非艾滋病重症耶氏肺孢子菌肺炎辅助糖皮质激素治疗:多中心双盲随机对照试验
该多中心双盲随机对照试验在法国27家医院纳入226例HIV阴性、免疫抑制、微生物学确诊耶氏肺孢子菌肺炎且抗肺孢子菌治疗不足7天的急性呼吸衰竭患者,随机接受甲泼尼龙静脉方案(第1-5天30mg每日两次,第6-10天30mg每日一次,至第21天20mg每日一次)或安慰剂。意向性治疗人群为安慰剂组111例、激素组107例,28天全因死亡率分别为32.4%与21.5%,平均差10.9%(95%CI -0.9至22.5),p=0.069,未达统计学显著。两组安全性结局无显著差异,包括继发感染和胰岛素需求。作者结论为辅助糖皮质激素未显著降低28天死亡率。
要点
- HIV阴性免疫抑制的耶氏肺孢子菌肺炎急性呼吸衰竭患者中,辅助甲泼尼龙组28天死亡率21.5%(23/107) vs 安慰剂组32.4%(36/111),平均差10.9%(95%CI -0.9至22.5),p=0.069,未达统计学显著。
- 该试验纳入微生物学确诊、抗肺孢子菌治疗不足7天、年龄≥18岁的轻至重度低氧血症患者,随机时95%(208/226)在ICU或中间监护病房。
- 激素方案为甲泼尼龙静脉给药:第1-5天30mg每日两次,第6-10天30mg每日一次,第11-21天20mg每日一次;从诊断到启动激素中位时间3天(IQR 2-5)。
- 两组安全性结局无显著差异:继发感染安慰剂组34.2%(38例) vs 激素组23.4%(25例);胰岛素需求安慰剂组22.5%(25例) vs 激素组30.8%(33例)。
- 作者结论:在HIV阴性免疫抑制的耶氏肺孢子菌肺炎患者中,辅助糖皮质激素未显著降低28天全因死亡率。
适用人群与场景
- 年龄≥18岁、HIV阴性免疫抑制、急性呼吸衰竭伴轻至重度低氧血症、微生物学确诊耶氏肺孢子菌肺炎、抗肺孢子菌治疗持续时间不足7天的患者。
- 随机时95%(208/226)患者在ICU或中间监护病房;随机分层因素包括中心、入组前>1个月开始的长期糖皮质激素治疗、基础疾病(恶性肿瘤 vs 其他)、随机时氧需求(<6 vs ≥6 L/min)。
诊断标准与关键阈值
- 微生物学确诊耶氏肺孢子菌肺炎。
- 急性呼吸衰竭伴轻至重度低氧血症。
- 抗肺孢子菌治疗持续时间<7天。
- 年龄≥18岁。
处置流程与药物剂量
- 激素组:甲泼尼龙静脉给药,第1-5天30mg每日两次,第6-10天30mg每日一次,第11-21天20mg每日一次,总疗程21天。
- 安慰剂组:等渗盐水静脉给药,2mL或3mL注射器。
- 从耶氏肺孢子菌肺炎诊断到启动激素治疗的中位时间为3天(IQR 2-5);试验治疗实际给药中位13天(范围7-20)。
研究设计与关键结果
- 多中心、双盲、随机对照试验,法国27家医院,2017年2月23日至2024年2月23日筛查466例,随机226例(安慰剂组114例、激素组112例),ITT人群安慰剂组111例、激素组107例。
- 中位年龄67岁(IQR 59-73);男性126例(58%),女性92例(42%)。
- 主要终点28天全因死亡率:安慰剂组32.4%(36/111) vs 激素组21.5%(23/107),平均差10.9%(95%CI -0.9至22.5),p=0.069,未达统计学显著。
- 继发感染:安慰剂组34.2%(38例,95%CI 25.4-43.1) vs 激素组23.4%(25例,95%CI 15.3-31.4),无显著差异。
- 胰岛素需求:安慰剂组22.5%(25例,95%CI 15.1-31.4) vs 激素组30.8%(33例,95%CI 22.3-40.5),无显著差异。
证据类型、等级与局限
- 证据类型:多中心、双盲、随机对照试验。
- 作者结论:在HIV阴性免疫抑制的耶氏肺孢子菌肺炎患者中,辅助糖皮质激素未显著降低28天全因死亡率。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于HIV阴性免疫抑制的耶氏肺孢子菌肺炎急性呼吸衰竭患者,辅助甲泼尼龙21天方案未显著降低28天全因死亡率(32.4% vs 21.5%,p=0.069),不能据此推荐常规使用。
- 该试验纳入抗肺孢子菌治疗不足7天且微生物学确诊的患者,随机时95%在ICU或中间监护病房;不适用于HIV阳性患者或未确诊患者。
- 两组继发感染和胰岛素需求无显著差异,但激素组胰岛素需求数值上高于安慰剂组(30.8% vs 22.5%),原文未报告统计学显著性差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Pneumocystis jirovecii pneumonia in HIV-negative immunocompromised patients has a hospital mortality rate of 30-50%. Adjunctive corticosteroids improve outcomes of P jirovecii pneumonia in HIV-positive patients. The aim of this trial was to assess the effects of early adjunctive corticosteroid therapy for 21 days in HIV-negative patients with P jirovecii pneumonia responsible for acute hypoxaemia respiratory failure.
METHODS: This multicentre, double-blind, randomised controlled trial was conducted at 27 hospitals in France. We included patients with acute respiratory failure, aged 18 years or older with mild-to-severe hypoxaemia, microbiological documentation of P jirovecii pneumonia, and anti-Pneumocystis treatment duration of less than 7 days. Patients were randomly assigned (1:1) to the corticosteroid group (adjunctive corticosteroid therapy of methylprednisolone intravenously, 30 mg twice per day from days 1 to 5, 30 mg once per day from days 6 to 10, and 20 mg once per day until day 21) or placebo group (2 mL or 3 mL syringes of isotonic saline intravenously) using a web-based system. Permutation blocks of fixed size unknown to the local investigators were used. Stratification factors were centre, long-term corticosteroid treatment started more than 1 month before enrolling in the trial, underlying disease (malignancy vs other), and oxygen needs at randomisation (<6 vs ≥6 L per min). The primary outcome was all-cause 28-day mortality defined as the proportion of patients who died within 28 days, analysed in the intention-to-treat (ITT) population. This trial was registered on ClinicalTrials.gov, NCT02944045 (closed).
FINDINGS: From Feb 23, 2017, to Feb 23, 2024, 466 patients with acute respiratory failure were assessed for eligibility. Of those, 240 were excluded and 226 patients were randomly assigned (114 assigned to the placebo group and 112 assigned to the corticosteroid group). The ITT population included 111 patients in the placebo group and 107 in the corticosteroid group. Median age was 67 years (IQR 59-73). 126 (58%) patients were male and 92 (42%) were female. Nearly all patients (208 [95%]) were in the ICU or intermediate care at randomisation. The median time from P jirovecii pneumonia diagnosis to corticosteroid therapy initiation was 3 days (IQR 2-5). Patients received trial treatment for 13 days (range 7-20). All-cause 28-day mortality occurred in 36 (32·4%) patients in the placebo group versus 23 (21·5%) in the corticosteroid group (mean difference 10·9% [95% CI -0·9 to 22·5]; p=0·069). There were no significant differences in safety outcomes between groups, especially for all secondary infections (38 [34·2%; 95% CI 25·4 to 43·1] patients in the placebo group vs 25 [23·4%; 15·3 to 31·4] in the corticosteroid group) or insulin needs (25 [22·5%; 15·1 to 31·4] vs 33 [30·8%; 22·3 to 40·5]).
INTERPRETATION: In immunocompromised HIV-negative patients with P jirovecii pneumonia, adjunctive corticosteroid treatment did not significantly decrease 28-day mortality.
FUNDING: French Ministry of Health.
参考来源
- Lemiale V, Resche-Rigon M, Zerbib Y, et al. Adjunctive corticosteroids in non-AIDS patients with severe Pneumocystis jirovecii pneumonia (PIC): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med. 2025. PMID: 40652952. doi:10.1016/S2213-2600(25)00125-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。